Summary:
Phase III study to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
Qualified Participants Must:
• Have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
•
Be 40 years of age or older.
•
Be a current or ex-smoker
Qualified Participants May Receive:
Study related medication and care at no cost. Eligible participants will be compensated for time and travel.